FindTrial
Sign In

Nivolumab Injectable Product

DRUG3 trials

Sponsors

Teclison Ltd., University of Rochester, Baylor College of Medicine

Conditions

Ewing SarcomaGastric CancerHER-2 Protein OverexpressionHepatocellular CarcinomaOsteosarcomaPancreatic CancerPancreatic Ductal AdenocarcinomaRhabdomyosarcoma

Phase 1

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Active, not recruitingNCT04477343
University of RochesterPancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Start: 2020-11-23End: 2026-12-31Target: 20Updated: 2026-07-06
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RecruitingNCT04995003
Baylor College of MedicineEwing Sarcoma, HER-2 Protein Overexpression, Osteosarcoma +5
Start: 2021-12-07End: 2043-06-30Target: 25Updated: 2026-01-22

Phase 2

Combination of TATE and PD-1 Inhibitor in Liver Cancer
RecruitingNCT03259867
Teclison Ltd.Gastric Cancer, Hepatocellular Carcinoma
Start: 2017-07-01End: 2027-06-30Target: 54Updated: 2026-04-16

Related Papers

A phase 2, open-label single-arm, multi-center study of trans-arterial tirapazamine embolization (TATE) combined with nivolumab (nivo) in patients with advanced immunotherapy-refractory hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2026-01-10
A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma.
Journal of Clinical Oncology2022-01-199 citations